Similarly, Hall et al. found that 5.2% of women under 50 years of age with carcinoma in situ (LCIS and DCIS) had BRCA1/2 mutations, with BRCA2 mutations being more common than BRCA1 [13]. The gene discussed is BRCA2; the disease is in situ carcinoma.